The next generation of novel low-density lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors

Pharmacological Research

Volumn 73, Issue , 2013, Pages 27-34

  Shen, Li ^a   Peng, Hongchun ^b   Xu, Danyan ^a   Zhao, Shuiping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CHANGSHA CENTRAL HOSPITAL   (China)

Author keywords

Dyslipidemia; LDL cholesterol Gain of function mutation; LDL receptor; PCSK9 inhibitor; Proprotein convertase subtilisin kexin 9

Indexed keywords

ALIROCUMAB; AMG 145; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ATORVASTATIN; BERBERINE; BEZAFIBRATE; CERIVASTATIN; COMPACTIN; EZETIMIBE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONOCLONAL ANTIBODY 1; MONOCLONAL ANTIBODY 1B20; MONOCLONAL ANTIBODY J10; MONOCLONAL ANTIBODY J16; PITAVASTATIN; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITOR; SERINE PROTEINASE; SIMVASTATIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTISENSE THERAPY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; GAIN OF FUNCTION MUTATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MUTATOR GENE; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 GENE; PROTEIN TARGETING; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; MUTATION; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS;

EID: 84878388937     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.04.001     Document Type: Review

References (54)

1. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis British Medical Journal 326 2003 1423
2. M.S. Brown, and J.L. Goldstein Biomedicine. Lowering LDL - not only how low, but how long? Science 311 2006 1721 1723
3. T.R. Joy Novel therapeutic agents for lowering low density lipoprotein cholesterol Pharmacology & Therapeutics 135 2012 31 43
4. B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, and E.H. Barnes The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
5. N.G. Seidah, S. Benjannet, L. Wickham, J. Marcinkiewicz, S.B. Jasmin, and S. Stifani The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation Proceedings of the National Academy of Sciences of the United States of America 100 2003 928 933
6. M. Abifadel, M. Varret, J.P. Rabes, D. Allard, K. Ouguerram, and M. Devillers Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nature Genetics 34 2003 154 156
7. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease New England Journal of Medicine 354 2006 1264 1272
8. N.G. Seidah, and A. Prat The biology and therapeutic targeting of the proprotein convertases Nature Reviews Drug Discovery 11 2012 367 383
9. C.J. Duff, and N.M. Hooper PCSK9: an emerging target for treatment of hypercholesterolemia Expert Opinion on Therapeutic Targets 15 2011 157 168
10. K.N. Maxwell, and J.L. Breslow Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype Proceedings of the National Academy of Sciences of the United States of America 101 2004 7100 7105
11. S. Rashid, D.E. Curtis, R. Garuti, N.N. Anderson, Y. Bashmakov, and Y.K. Ho Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 Proceedings of the National Academy of Sciences of the United States of America 102 2005 5374 5379
12. T.A. Lagace, D.E. Curtis, R. Garuti, M.C. McNutt, S.W. Park, and H.B. Prather Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice Journal of Clinical Investigation 116 2006 2995 3005
13. X.M. Sun, E.R. Eden, I. Tosi, C.K. Neuwirth, D. Wile, and R.P. Naoumova Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia Human Molecular Genetics 14 2005 1161 1169
14. O.N. Akram, A. Bernier, F. Petrides, G. Wong, G. Lambert, and Beyond LDL cholesterol, a new role for PCSK9 Arteriosclerosis, Thrombosis, and Vascular Biology 30 2010 1279 1281
15. A. Baass, G. Dubuc, M. Tremblay, E.E. Delvin, J. O'Loughlin, and E. Levy Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents Clinical Chemistry 55 2009 1637 1645
16. S.G. Lakoski, T.A. Lagace, J.C. Cohen, J.D. Horton, and H.H. Hobbs Genetic and metabolic determinants of plasma PCSK9 levels Journal of Clinical Endocrinology and Metabolism 94 2009 2537 2543
17. C. Le May, S. Kourimate, C. Langhi, M. Chetiveaux, A. Jarry, and C. Comera Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia Arteriosclerosis, Thrombosis, and Vascular Biology 29 2009 684 690
18. B. Herbert, D. Patel, S.N. Waddington, E.R. Eden, A. McAleenan, and X.M. Sun Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control Arteriosclerosis, Thrombosis, and Vascular Biology 30 2010 1333 1339
19. D. Cunningham, D.E. Danley, K.F. Geoghegan, M.C. Griffor, J.L. Hawkins, and T.A. Subashi Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia Nature Structural & Molecular Biology 14 2007 413 419
20. C. Stefanutti, C. Morozzi, and S. Di Giacomo New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia Current Medicinal Chemistry 19 2012 4861 4868
21. J. Mayne, T. Dewpura, A. Raymond, M. Cousins, A. Chaplin, and K.A. Lahey Plasma PCSK9 levels are significantly modified by statins and fibrates in humans Lipids in Health and Disease 7 2008 22
22. G. Dubuc, M. Tremblay, G. Pare, H. Jacques, J. Hamelin, and S. Benjannet A new method for measurement of total plasma PCSK9: clinical applications Journal of Lipid Research 51 2010 140 149
23. G. Welder, I. Zineh, M.A. Pacanowski, J.S. Troutt, G. Cao, and R.J. Konrad High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol Journal of Lipid Research 51 2010 2714 2721
24. B. Dong, M. Wu, H. Li, F.B. Kraemer, K. Adeli, and N.G. Seidah Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters Journal of Lipid Research 51 2010 1486 1495
25. S. Kourimate, C. Le May, C. Langhi, A.L. Jarnoux, K. Ouguerram, and Y. Zair Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9 Journal of Biological Chemistry 283 2008 9666 9673
26. J.S. Troutt, W.E. Alborn, G. Cao, and R.J. Konrad Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels Journal of Lipid Research 51 2010 345 351
27. T. Noguchi, J. Kobayashi, K. Yagi, A. Nohara, N. Yamaaki, and M. Sugihara Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study Atherosclerosis 217 2011 165 170
28. J. Davignon, and G. Dubuc Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels Transactions of the American Clinical and Climatological Association 120 2009 163 173
29. J. Cameron, T. Ranheim, M.A. Kulseth, T.P. Leren, and K.E. Berge Berberine decreases PCSK9 expression in HepG2 cells Atherosclerosis 201 2008 266 273
30. M. Denis, J. Marcinkiewicz, A. Zaid, D. Gauthier, S. Poirier, and C. Lazure Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice Circulation 125 2012 894 901
31. R.J. Konrad, J.S. Troutt, and G. Cao Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents Lipids in Health and Disease 10 2011 38
32. M.J. Graham, K.M. Lemonidis, C.P. Whipple, A. Subramaniam, B.P. Monia, and S.T. Crooke Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice Journal of Lipid Research 48 2007 763 767
33. N. Gupta, N. Fisker, M.C. Asselin, M. Lindholm, C. Rosenbohm, and H. Orum A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo PLoS ONE 5 2010 e10682
34. M.W. Lindholm, J. Elmen, N. Fisker, H.F. Hansen, R. Persson, and M.R. Moller PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates Molecular Therapy 20 2012 376 381
35. M. Frank-Kamenetsky, A. Grefhorst, N.N. Anderson, T.S. Racie, B. Bramlage, and A. Akinc Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates Proceedings of the National Academy of Sciences of the United States of America 105 2008 11915 11920
36. C.J. Duff, M.J. Scott, I.T. Kirby, S.E. Hutchinson, S.L. Martin, and N.M. Hooper Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor Biochemical Journal 419 2009 577 584
37. L. Zhang, T. McCabe, J.H. Condra, Y.G. Ni, L.B. Peterson, and W. Wang An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes International Journal of Biological Sciences 8 2012 310 327
38. H. Liang, J. Chaparro-Riggers, P. Strop, T. Geng, J.E. Sutton, and D. Tsai Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates Journal of Pharmacology and Experimental Therapeutics 340 2012 228 236
39. J. Chaparro-Riggers, H. Liang, R.M. DeVay, L. Bai, J.E. Sutton, and W. Chen Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 Journal of Biological Chemistry 287 2012 11090 11097
40. C.S. Dias, A.J. Shaywitz, S.M. Wasserman, B.P. Smith, B. Gao, and D.S. Stolman Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins Journal of the American College of Cardiology 60 2012 1888 1898
41. R.P. Giugliano, N.R. Desai, P. Kohli, W.J. Rogers, R. Somaratne, and F. Huang Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
42. F. Raal, R. Scott, R. Somaratne, I. Bridges, G. Li, and S.M. Wasserman Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
43. M.J. Koren, R. Scott, J.B. Kim, B. Knusel, T. Liu, and L. Lei Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
44. D. Sullivan, A.G. Olsson, R. Scott, J.B. Kim, A. Xue, and V. Gebski Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial Journal of the American Medical Association 308 2012 2497 2506
45. E.A. Stein, S. Mellis, G.D. Yancopoulos, N. Stahl, D. Logan, and W.B. Smith Effect of a monoclonal antibody to pcsk9 on ldl cholesterol New England Journal of Medicine 366 2012 1108 1118
46. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease. SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy Journal of the American College of Cardiology 59 2012 2344 2353
47. E.A. Stein, D. Gipe, J. Bergeron, D. Gaudet, R. Weiss, and R. Dufour Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
48. E.M. Roth, J.M. McKenney, C. Hanotin, G. Asset, and E.A. Stein Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia New England Journal of Medicine 367 2012 1891 1900
49. P. Labonte, S. Begley, C. Guevin, M.C. Asselin, N. Nassoury, and G. Mayer PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression Hepatology 50 2009 17 24
50. A. Zaid, A. Roubtsova, R. Essalmani, J. Marcinkiewicz, A. Chamberland, and J. Hamelin Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration Hepatology 48 2008 646 654
51. M. Mbikay, F. Sirois, J. Mayne, G.S. Wang, A. Chen, and T. Dewpura PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities FEBS Letters 584 2010 701 706
52. V. Sharotri, D.M. Collier, D.R. Olson, R. Zhou, and P.M. Snyder Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9) Journal of Biological Chemistry 287 2012 19266 19274
53. D.A. Marais, D.J. Blom, F. Petrides, Y. Goueffic, and G. Lambert Proprotein convertase subtilisin/kexin type 9 inhibition Current Opinion in Lipidology 23 2012 511 517
54. R.A. Vogel PCSK9 inhibition: the next statin? Journal of the American College of Cardiology 59 2012 2354 2355